Ceftriaxone in the Management of Bipolar Depression
Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient,
placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar
disorder, currently depressed, who have failed to respond to conventional treatments.